Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.

Antimicrobial Agents and Chemotherapy
K Weiss, J R Lapointe

Abstract

Previous studies have demonstrated synergy between an aminoglycoside and a beta-lactam for treating Pseudomonas aeruginosa infections. Cystic fibrosis patients are prone to infection by this bacterium, which becomes very resistant with recurrent antibiotic treatments. The purpose of this study was to evaluate the susceptibility patterns of 122 isolates of P. aeruginosa isolated from cystic fibrosis patients to five individual antibiotics (tobramycin, ceftazidime, piperacillin, ticarcillin, and imipenem) and to four antibiotic combinations (tobramycin associated with one of the other antibiotics). Strains were selected because of their resistance to individual antimicrobial agents, which ranged from 21.3% for imipenem to 56.5% for tobramycin. By using an automated broth microdilution method, we were able to demonstrate synergy against 39 strains (32%) with tobramycin-ticarcillin, against 38 strains (31%) with tobramycin-piperacillin, against 47 strains (39%) with tobramycin-ceftazidime, and against 23 strains (19%) with tobramycin-imipenem. Of the 122 isolates, 77 (63%) were rendered significantly susceptible to at least one of the four antibiotic combinations by synergy. These results suggest that when appropriate technology is...Continue Reading

References

May 1, 1978·Antimicrobial Agents and Chemotherapy·H S Heineman, W M Lofton
Feb 1, 1978·The Journal of Infectious Diseases·M C Berenbaum
Nov 1, 1991·Antimicrobial Agents and Chemotherapy·J A Korvick, V L Yu
Jan 1, 1991·Clinical Microbiology Reviews·P H Gilligan
Aug 1, 1988·Chest·G DöringN Høiby
Feb 1, 1984·The Journal of Pediatrics·A IslesH Levison
Jun 1, 1993·The Journal of Antimicrobial Chemotherapy·J W MoutonA M Horrevorts
Jan 1, 1993·The Journal of Pediatrics·S C FitzSimmons

❮ Previous
Next ❯

Citations

Jan 13, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B BalkeS Häussler
Nov 7, 1995·Biochimica Et Biophysica Acta·L B VogelD J Fujita
Jun 20, 2001·FEBS Letters·P CramerA R Kornblihtt
Nov 10, 2000·Biochimica Et Biophysica Acta·H Jumaa, P J Nielsen
Sep 6, 2002·Biochimica Et Biophysica Acta·Kenneth James Howe
Apr 14, 1999·Australian and New Zealand Journal of Medicine·J M WolterJ G McCormack
Jun 24, 1999·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Y L WuV N Tariq
Sep 5, 2009·American Journal of Respiratory and Critical Care Medicine·Patrick A FlumeUNKNOWN Clinical Practice Guidelines for Pulmonary Therapies Committee
Jan 24, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Sie Huey LeeReginald B H Tan
Jul 17, 2013·Revista Da Sociedade Brasileira De Medicina Tropical·Denissani Aparecida Ferrari dos SantosRoberto Martinez
Sep 5, 2019·The Cochrane Database of Systematic Reviews·Jayesh BhattAlan R Smyth
Mar 30, 2017·The Cochrane Database of Systematic Reviews·Alan R SmythSarah J Nevitt
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·S P ConwayD G Peckham
Apr 1, 2008·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Sarah K WassilJames W White
Jun 9, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jonathan D CogenRonald L Gibson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.